Apollomics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-08$22.52 RISE2026-04-28$12.85 PEAK2026-05-04$16.47 116d | -42.9% 110d | Missed | Missed | — | — | +28.1% 6d | Missed |
DROP2025-10-17$36.65 RISE2026-01-28$17.85 PEAK2026-02-02$21.77 108d | -51.3% 103d | Missed | Missed | — | — | +21.9% 5d | Missed |
DROP2025-10-17$36.65 RISE2025-10-30$11.61 PEAK2025-11-14$24.54 28d | -68.3% 13d | Missed | Missed | — | — | +111.4% 15d | Missed |
DROP2025-05-22$7.26 RISE2025-08-29$3.93 PEAK2025-10-17$36.65 148d | -45.8% 99d | Missed | Missed | — | — | +832.1% 49d | Missed |
DROP2025-03-20$10.39 RISE2025-06-23$5.34 PEAK2025-09-17$18.43 181d | -48.6% 95d | Missed | Missed | — | — | +245.2% 86d | Missed |
DROP2025-01-06$11.20 RISE2025-05-15$4.63 PEAK2025-05-22$7.26 136d | -58.7% 129d | Missed | Missed | — | — | +57.0% 7d | Missed |
DROP2024-12-02$11.53 RISE2025-04-07$5.09 PEAK2025-05-22$7.26 171d | -55.9% 126d | Missed | Missed | — | — | +42.6% 45d | Missed |
DROP2024-11-18$19.40 RISE2025-02-28$6.20 PEAK2025-03-20$10.39 122d | -68.0% 102d | Missed | Missed | — | — | +67.6% 20d | Missed |
DROP2024-11-18$19.40 RISE2024-12-10$7.16 PEAK2024-12-24$11.25 36d | -63.1% 22d | Missed | Missed | — | — | +57.1% 14d | Missed |
DROP2024-04-25$47.10 RISE2024-09-03$11.30 PEAK2024-11-18$19.40 207d | -76.0% 131d | Missed | Missed | — | — | +71.7% 76d | Missed |
DROP2023-09-28$394.00 RISE2024-02-06$58.10 PEAK2024-03-04$76.90 158d | -85.3% 131d | Missed | Missed | — | — | +32.4% 27d | Missed |
DROP2023-08-15$526.50 RISE2023-12-20$76.50 PEAK2024-01-16$99.70 154d | -85.5% 127d | Missed | Missed | — | — | +30.3% 27d | Missed |
DROP2023-06-29$589.00 RISE2023-10-26$56.80 PEAK2023-11-27$114.00 151d | -90.4% 119d | Missed | Missed | — | — | +100.7% 32d | Missed |
DROP2023-03-30$2,940.00 RISE2023-05-04$393.00 PEAK2023-06-29$589.00 91d | -86.6% 35d | Missed | Missed | — | — | +49.9% 56d | Missed |
No scored news yet for a sentiment trend.
Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential.To date, more than 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trials.Phase 2/3 IND submission for development of vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries for the treatment of NSCLC. FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSW
Apollomics (NASDAQ:APLM) reported quarterly losses of $(7.57) per share. This is a 85.66 percent increase over losses of $(52.80) per share from the same period last year. The company reported $8.500 million in sales
FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the “Note”) with Mr. Hung-Wen (Howard) Chen, the Company’s Chairman and Chief Executive Officer, on March 30, 2026. The $2.0 million in proceeds from the Note are intended to provide the Company with necessary working capital to support clinical development programs and general corpor
Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the "Note") with Mr. Hung-Wen (Howard) Chen, the Company's
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025. First Half 2025 Financial Results Ended June 20, 2025 Cash, cash equivalents, bank deposits and money market funds as of June 30, 2025, were $2
On December 11, 2025, Apollomics Inc. (the "Company") issued a formal notice of termination to Edison Oncology Holding Corporation ("Edison") regarding the Development and License Agreement dated January 31, 2021,
FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited (together, “TWVC”), entities represented by Triwise Capital Management Ltd, in connection with the litigation previously filed in the Grand Court of the Cayman Islands (the “Cayman Litigation”
-SEC Filing
FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company’s board of directors (“Board”) and composition of committees. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh’s resignation was not related to any disagreement with the Company. Pursuant to a meeting of the Board on Nov
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| APLM | -12.76% | -29.85% | -24.31% | +131.97% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -15.73% | -24.13% | -20.87% | +119.28% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| DEShaw | quant | 318.5K | $6.37K | 0.00% | Unchanged | 2026-03-31 |